Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 758 publications

Laboratory Monitoring in Patients Receiving Emicizumab.

Laboratory Monitoring in Patients Receiving Emicizumab.

Journal: Hamostaseologie
Published: October 09, 2025

Laboratory Assessment of Emicizumab Levels in Hemophilia A: Influence of Assay Selection on Reported Results.

Laboratory Assessment of Emicizumab Levels in Hemophilia A: Influence of Assay Selection on Reported Results.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: September 26, 2025

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis.

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis.

Journal: BMJ open
Published: September 10, 2025

Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness.

Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness.

Journal: Seminars in thrombosis and hemostasis
Published: September 09, 2025

Assessment of emicizumab levels in EDTA plasma.

Assessment of emicizumab levels in EDTA plasma.

Journal: Research and practice in thrombosis and haemostasis
Published: August 22, 2025

Long-Term Joint Function and Quality of Life Following Emicizumab Prophylaxis in Severe Hemophilia A: A Single-Center Study From Goa, India.

Long-Term Joint Function and Quality of Life Following Emicizumab Prophylaxis in Severe Hemophilia A: A Single-Center Study From Goa, India.

Journal: Cureus
Published: August 22, 2025

Factor VIII Inhibitors in the Context of Renal Cell Carcinoma and Hemophilia A: A Tale of Two Causes.

Factor VIII Inhibitors in the Context of Renal Cell Carcinoma and Hemophilia A: A Tale of Two Causes.

Journal: Cureus
Published: July 23, 2025

Development and expression of a factor X-derived recombinant protein for ELISA-based detection of Emicizumab.

Development and expression of a factor X-derived recombinant protein for ELISA-based detection of Emicizumab.

Journal: Protein expression and purification
Published: July 23, 2025

Four-Year Emicizumab Treatment in an Elderly Patient With Acquired Hemophilia A: A Case Report on Perioperative Management Along With a Literature Review.

Four-Year Emicizumab Treatment in an Elderly Patient With Acquired Hemophilia A: A Case Report on Perioperative Management Along With a Literature Review.

Journal: Cureus
Published: July 23, 2025

Discovery and development of bispecific antibodies.

Discovery and development of bispecific antibodies.

Journal: Protein expression and purification
Published: July 14, 2025

Effective but Elusive: Emicizumab for Hemophilia A in India.

Effective but Elusive: Emicizumab for Hemophilia A in India.

Journal: Indian journal of pediatrics
Published: July 10, 2025

Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State.

Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: July 08, 2025
Showing 1-12 of 758

Last Updated: 10/31/2025